Lilly lifts its Lebanon, Indiana build to $9 billion to make tirzepatide ingredient

What was announced

Lilly said it would raise its investment at the LEAP Research and Innovation District in Lebanon, Indiana, to about $9 billion. The first plan, in 2022, was about $3.7 billion. Lilly called the new total the largest manufacturing investment in its history.

What the site makes

The plant is built to make active pharmaceutical ingredient, the peptide itself. Filling it into pens and vials happens at other sites. Lilly named tirzepatide as the first product.

Why the ingredient matters

A peptide such as tirzepatide is built from amino acids step by step, then purified. That chemistry takes large reactors, a lot of solvent and long purification runs. When demand jumps, a company cannot simply add a shift; it needs more of these lines.

Timeline

Lilly said production would start toward the end of 2026 and grow after that. New drug plants also need inspection and approval before their output can be sold, so the first commercial lot usually comes months after the building is finished.

The caveat

Big numbers in factory announcements usually cover many years and several buildings. The $9 billion is a plan, not money already spent.